0001209191-12-021640.txt : 20120403 0001209191-12-021640.hdr.sgml : 20120403 20120403203533 ACCESSION NUMBER: 0001209191-12-021640 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120330 FILED AS OF DATE: 20120403 DATE AS OF CHANGE: 20120403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WOOD JULIANNA R CENTRAL INDEX KEY: 0001282660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 12739969 MAIL ADDRESS: STREET 1: 3031 RESEARCH DR STREET 2: BLDG A CITY: RICHMOND STATE: CA ZIP: 84806 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0305 4 2012-03-30 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001282660 WOOD JULIANNA R C/O ONYX PHARMACEUTICALS, INC. 249 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 VP, Public Affairs Common Stock 2012-03-30 4 A 0 4500 0.00 A 20897 D Common Stock 2012-03-30 4 A 0 4050 0.00 A 24947 D Common Stock 2012-04-02 4 D 0 317 36.5769 D 24630 D Common Stock 2012-04-02 4 D 0 474 36.5759 D 24156 D Common Stock 2012-04-02 4 D 0 442 36.5743 D 23714 D Common Stock 200 I Childrens' Trust Stock Option (Right to Buy) 37.68 2012-03-30 4 A 0 23000 0.00 A 2022-03-30 Common Stock 23000 23000 D Represents a restricted stock unit granted to the reporting person. The restricted stock unit vests annually over 3 years. Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones. Payment of exercise price or tax liability by delivering or withholding securities incident to receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. Shares sold pursuant to a 10b5-1 plan. Shares sold in compliance with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. Julianna Wood by /s/ Warren De Souza, Attorney-in-Fact 2012-04-03